Login Register Cart 0
Generic placeholder image

Current Nanomaterials

Editor-in-Chief

ISSN (Print): 2405-4615
ISSN (Online): 2405-4623

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Nano Sized ZnO/MnO2/Gd2O3 Ternary Heterostructures for Enhanced Photocatalysis

Author(s): Shubha Pranesh* and Jayalakshmi Nagaraju

Volume 5, Issue 1, 2020

Page: [36 - 46] Pages: 11

DOI: 10.2174/2405461504666191202105734

Abstract

Background: The cost of effluent treatment is not affordable by small scale industries especially in developing countries. Hence the effluent is discharged without treatment into water bodies. The dyes do not degrade easily and possess a major concern to be addressed. The aquatic life is highly affected and also leads to bio magnification of the chemicals through the food chain.

Objective: To synthesize a ternary hybrid structure for enhanced photocatalytic activity under visible light. It is intended to reduce toxicity caused by dyeing units.

Methods: Synthesized nanomaterials are characterized and used as photocatlyst for the degradation of methylene blue. In degradation experiment known weight of catalyst was added to known volume of an aqueous solution of dye at various concentrations. The solutions are aerated in dark for about 30 min. At the time of irradiation of light, known aliquot of the aqueous mixture was collected at an interval of constant time each from the reaction solution. The catalyst in the mixture was separated by centrifuging the mixture and absorbance was measured. The % of degradation of the dye can be determined knowing initial and final dye concentration.

Results: Heterostructures are characterized with analytical tools such as X-ray diffraction, Fourier transform infrared spectroscopy. Band gap of photocatlyst is calculated by application of UV-Vis spectroscopy. Morphology is seen using scanning electron microscopy and transmission electron microscopy. Distribution of constituent structures is observed with energy-dispersive X-ray (EDX) spectroscopy. The structures are used for photocatalytic degradation of methylene blue dye solution under UV and visible light irradiation. Heterostructures showed best performance under visible light.

Conclusion: The ternary hybrid nanostructure ZnO-MnO2-Gd2O3 was effectively prepared by a simple solution combustion method. The ternary compound shows wide range of absorption by expanding absorption band both in UV and visible regions. Structures showed better catalytic property under visible light.

Keywords: Photocatalysis, nano ternary heterostructure, methylene blue, nanomaterials, visible light, UV-Vis spectroscopy.

« Previous Next »
Graphical Abstract

[1]
Eldaw A. Nanotechnology in elevation of the worldwide impact of obesity and obesity-related diseases: potential roles in human health and disease. J Diabetes Sci Technol 2011; 5(4): 1005-8.
[http://dx.doi.org/10.1177/193229681100500424] [PMID: 21880244]
[2]
Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5(4): 505-15.
[http://dx.doi.org/10.1021/mp800051m] [PMID: 18672949]
[3]
Amandeep K, Harikumar SL. Controlled drug delivery approaches for rheumatoid arthritis. J Appl Pharm Sci 2012; 2(8): 21-32.
[4]
Arias J, Lopez-Viota M, Lopez-Viota J, Delgado AV. Development of iron/ethyl cellulose core/shell for biomedical applications. Int J Pharm 2007; 18(339): 237-45.
[http://dx.doi.org/10.1016/j.ijpharm.2007.02.028] [PMID: 17398048]
[5]
Azzazy HME, Mansour MMH, Kazmierczak SC. From diagnostics to therapy: prospects of quantum dots. Clin Biochem 2007; 40(13-14): 917-27.
[http://dx.doi.org/10.1016/j.clinbiochem.2007.05.018] [PMID: 17689518]
[6]
Barros MT, Balasubramaniam S, Jennings B. Comparative end-to-end analysis of Ca2+ signaling based molecular communication in biological tissues. IEEE Trans Commun 2015; 60(12): 5128.
[http://dx.doi.org/10.1109/TCOMM.2015.2487349]
[7]
Bawa R. Nanoparticle-based therapeutics in humans: a survey. Nanotechnol Law Bus 2008; 5: 135-55.
[8]
Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009; 38(6): 1759-82.
[http://dx.doi.org/10.1039/b806051g] [PMID: 19587967]
[9]
Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54(5): 631-51.
[http://dx.doi.org/10.1016/S0169-409X(02)00044-3] [PMID: 12204596]
[10]
Chahibi Y, Pierobon M, Song SO, Akyildiz IF. A molecular communication system model for particulate drug delivery systems. IEEE Trans Biomed Eng 2013; 60(12): 3468-83.
[http://dx.doi.org/10.1109/TBME.2013.2271503] [PMID: 23807425]
[11]
Chan WCW, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998; 281(5385): 2016-8.
[http://dx.doi.org/10.1126/science.281.5385.2016] [PMID: 9748158]
[12]
Cheng Y, Zhao L, Li Y, Xu T. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem Soc Rev 2011; 40(5): 2673-703.
[http://dx.doi.org/10.1039/c0cs00097c] [PMID: 21286593]
[13]
Coester CJ, Langer K, van Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake. J Microencapsul 2000; 17(2): 187-93.
[http://dx.doi.org/10.1080/026520400288427] [PMID: 10738694]
[14]
Cristian V. Nanotechnology in preclinical and clinical drug development. Int J Med Surg Sci 2014; 1(1): 73-93.
[15]
DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2015; 7(4): 548-64.
[http://dx.doi.org/10.1002/wnan.1329] [PMID: 25641955]
[16]
Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev 2012; 41(6): 2256-82.
[http://dx.doi.org/10.1039/C1CS15166E] [PMID: 22130549]
[17]
Emerich DF, Thanos CG. Nanotechnology and medicine. Expert Opin Biol Ther 2003; 3(4): 655-63.
[http://dx.doi.org/10.1517/14712598.3.4.655] [PMID: 12831370]
[18]
Frasco MF, Chaniotakis N. Bioconjugated quantum dots as fluorescent probes for bioanalytical applications. Anal Bioanal Chem 2010; 396(1): 229-40.
[http://dx.doi.org/10.1007/s00216-009-3033-0] [PMID: 19714321]
[19]
Felicetti L, Femminella M, Reali G, Lio P. Applications of molecular communications to medicine: a survey. Nano Commun Netw 2015; 7: 27-45.
[20]
Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005; 172(12): 1487-90.
[http://dx.doi.org/10.1164/rccm.200504-613PP] [PMID: 16151040]
[21]
Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn 2006; 6(3): 307-18.
[http://dx.doi.org/10.1586/14737159.6.3.307] [PMID: 16706735]
[22]
Haas SE, Bettoni CC, de Oliveira LK, Guterres SS, Dalla Costa T. Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo. Int J Antimicrob Agents 2009; 34(2): 156-61.
[http://dx.doi.org/10.1016/j.ijantimicag.2009.02.024] [PMID: 19369041]
[23]
Henderson CS, Madison AC, Shah A. Size matters--nanotechnology and therapeutics in rheumatology and immunology. Curr Rheumatol Rev 2014; 10(1): 11-21.
[http://dx.doi.org/10.2174/1573403X10666140914155926] [PMID: 25229497]
[24]
He H, Pham-Huy LA, Dramou P, Xiao D, Zuo P, Pham-Huy C. Carbon nanotubes: applications in pharmacy and medicine. BioMed Res Int 2013; 2013 578290
[http://dx.doi.org/10.1155/2013/578290] [PMID: 24195076]
[25]
Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Kumar MN. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release 2007; 119(2): 197-206.
[http://dx.doi.org/10.1016/j.jconrel.2007.02.004] [PMID: 17399839]
[26]
Jain KK. Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev Mol Diagn 2003; 3(2): 153-61.
[http://dx.doi.org/10.1586/14737159.3.2.153] [PMID: 12647993]
[27]
Jayaraj RL, Chandramohan V. Nanomedicines for Parkinson disease: current status and future perspective. Int J Pharm Bio Sci 2013; 4(1): 692-04.
[28]
Kuntworbe N, Al-Kassas R. Design and in vitro haemolytic evaluation of cryptolepine hydrochloride-loaded gelatine nanoparticles as a novel approach for the treatment of malaria. AAPS PharmSciTech 2012; 13(2): 568-81.
[http://dx.doi.org/10.1208/s12249-012-9775-6] [PMID: 22477022]
[29]
Feng L, Liu Z. Graphene in biomedicine: opportunities and challenges. Nanomedicine (Lond) 2011; 6(2): 317-24.
[http://dx.doi.org/10.2217/nnm.10.158] [PMID: 21385134]
[30]
Linazasoro G. Potential applications of nanotechnologies to Parkinson’s disease therapy. Parkinsonism Relat Disord 2008; 14(5): 383-92.
[http://dx.doi.org/10.1016/j.parkreldis.2007.11.012] [PMID: 18329315]
[31]
Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997; 49(4): 403-49.
[PMID: 9443165]
[32]
Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008; 5(4): 496-504.
[http://dx.doi.org/10.1021/mp800049w] [PMID: 18611037]
[33]
Mamo T, Moseman EA, Kolishetti N, et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) 2010; 5(2): 269-85.
[http://dx.doi.org/10.2217/nnm.10.1] [PMID: 20148638]
[34]
Mittal G, Kumar MN. Impact of polymeric nanoparticles on oral pharmacokinetics: a dose-dependent case study with estradiol. J Pharm Sci 2009; 98(10): 3730-4.
[http://dx.doi.org/10.1002/jps.21695] [PMID: 19189398]
[35]
Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19(3): 311-30.
[http://dx.doi.org/10.1096/fj.04-2747rev] [PMID: 15746175]
[36]
Nasiruddin M, Das S. Nanotechnology based approach in tuberculosis treatment. Tubercul Res and Treat 2017; 2017: 1-12.
[37]
Nakache E, Poulain N, Cand F. Biopolymer and polymer nanoparticles and their biomedical applications. In: Nalwa HS, Ed. . Handbook of nanostructure and nanotechnology. USA: Academic Press 2000; 5: pp. 577-35.
[http://dx.doi.org/10.1016/B978-012513760-7/50063-0]
[38]
Arias JL, López-Viota M, López-Viota J, Delgado AV. Nanoparticles loaded with diclofenac sodium for arthritis treatment. Int J Pharm 2009; 382(1): 270-6.
[PMID: 19712736]
[39]
Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B Biointerfaces 2010; 81(1): 263-73.
[http://dx.doi.org/10.1016/j.colsurfb.2010.07.020] [PMID: 20688493]
[40]
Aditya NP, Patankar S, Madhusudhan B, Murthy RS, Souto EB. Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity. Eur J Pharm Sci 2010; 40(5): 448-55.
[http://dx.doi.org/10.1016/j.ejps.2010.05.007] [PMID: 20493255]
[41]
Nazem A, Mansoori GA. Nanotechnology solutions for Alzheimer’s disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis 2008; 13(2): 199-223.
[http://dx.doi.org/10.3233/JAD-2008-13210] [PMID: 18376062]
[42]
Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010; 9(8): 615-27.
[http://dx.doi.org/10.1038/nrd2591] [PMID: 20616808]
[43]
Pham CT. Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011; 3(6): 607-19.
[http://dx.doi.org/10.1002/wnan.157] [PMID: 21837725]
[44]
Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006; 5(8): 1909-17.
[http://dx.doi.org/10.1158/1535-7163.MCT-06-0141] [PMID: 16928810]
[45]
Rosi NL, Mirkin CA. Nanostructures in biodiagnostics. Chem Rev 2005; 105(4): 1547-62.
[http://dx.doi.org/10.1021/cr030067f] [PMID: 15826019]
[46]
Shivkumar HG, Gowda DV, Krishna RSM. Nanoparticles-targeting neuro therapeutic agents through the blood brain barrier. Indian Drugs 2005; 42: 709-11.
[47]
Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine (Lond) 2007; 3(1): 20-31.
[http://dx.doi.org/10.1016/j.nano.2006.11.008] [PMID: 17379166]
[48]
Satija J, Sai VVR, Mukherji S. Dendrimers in biosensors: concepts and applications. J Mater Chem 2011; 21: 14367-86.
[http://dx.doi.org/10.1039/c1jm10527b]
[49]
Singh OP, Nehru RM. Nanotechnology and cancer treatment. Asian J Exp Sci 2008; 22(2): 6.
[50]
Shen M, Shi X. Dendrimer-based organic/inorganic hybrid nanoparticles in biomedical applications. Nanoscale 2010; 2(9): 1596-610.
[http://dx.doi.org/10.1039/c0nr00072h] [PMID: 20820690]
[51]
Souto EB, Muller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. In: Barrett JE, Ed. . Handbook of Experimental Pharmacology Springer Nature:. Switzerland 2010; pp. 115-41.
[52]
Deb S, Ghosh K, Shetty SD. Nanoimaging in cardiovascular diseases: Current state of the art. Indian J Med Res 2015; 141(3): 285-98.
[http://dx.doi.org/10.4103/0971-5916.156557] [PMID: 25963489]
[53]
Timko B. Advances in drug delivery. Annu Rev Mater Res 2011; 41: 1-20.
[http://dx.doi.org/10.1146/annurev-matsci-062910-100359] [PMID: 21143129]
[54]
Varshney HM, Rajnish K, Shailender M. Novel approaches for insulin delivery: current status. Int J of Therap Appl 2012; 7: 25-31.
[55]
Vashist SK, Zheng D, Al-Rubeaan K, Luong JHT, Sheu FS. Advances in carbon nanotube based electrochemical sensors for bioanalytical applications. Biotechnol Adv 2011; 29(2): 169-88.
[http://dx.doi.org/10.1016/j.biotechadv.2010.10.002] [PMID: 21034805]
[56]
Vashist SK, Venkatesh AG, Mitsakakis K. Nanotechnology based biosensors and diagnostics: technology push versus industrial/healthcare requirements. Bionanoscience 2012; 2: 115-26.
[http://dx.doi.org/10.1007/s12668-012-0047-4]
[57]
Zhang X, Liu J, Qiao H, et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 2010; 120: 128.
[http://dx.doi.org/10.1016/j.powtec.2009.09.004]
[58]
Mohanta BC, Palei NN, Surendran V, Dinda SC, Rajangam J. Lipid based nanoparticles: current strategies for brain tumor targeting. Current Nanomater 2010; 4(2): 1-18.
[59]
Patil M, Mehta DS, Guvva S. Future impact of nanotechnology on medicine and dentistry. J Indian Soc Periodontol 2008; 12(2): 34-40.
[http://dx.doi.org/10.4103/0972-124X.44088] [PMID: 20142942]
[60]
Saadeh Y, Vyas D. Nanorobotic applications in medicine: current proposals and designs. Am J Robot Surg 2014; 1(1): 4-11.
[http://dx.doi.org/10.1166/ajrs.2014.1010] [PMID: 26361635]
[61]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[62]
Tile VG, Suraj HS, Uday BM, Sahana SG. Recent trends in nanotechnology and its future scope-a review. Int J on Emerg Techn 2016; 7(2): 377-85.

Rights & Permissions Print Cite
Article Metrics
18
© 2024 Bentham Science Publishers | Privacy Policy